PEPTOKING
NO

Studier å følge med på

Pågående og nylig avsluttede kliniske studier av peptidene i katalogen. Fase, status, størrelse og datoer kommer fra ClinicalTrials.gov og endres når sponsorene oppdaterer registeret.

Primær avslutning er når den siste deltakeren er målt for hovedutfallet; resultatene kommer vanligvis flere måneder senere. Registerdata kontrollert 2. okt. 2026.

Resultater ventes

  1. Fase 3Pågår, rekrutterer ikke

    STEP Young(åpner kilden i en ny fane)

    A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

    Primær avslutning: 15. okt. 2025210 deltakereSponsor: Novo Nordisk A/SNCT05726227

  2. Fase 3Pågår, rekrutterer ikke

    Afamelanotide plus NB-UVB in vitiligo(åpner kilden i en ny fane)

    A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

    Forventet primær avslutning: desember 2025200 deltakereSponsor: Clinuvel, Inc.NCT06109649

  3. Fase 2, Fase 3Pågår, rekrutterer ikke

    Intranasal oxytocin for chronic pain(åpner kilden i en ny fane)

    Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain

    Forventet primær avslutning: 31. mars 2026336 deltakereSponsor: Memorial University of NewfoundlandNCT04903002

  4. Fase 2Rekrutterer

    Mazdutide in MASH(åpner kilden i en ny fane)

    A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Forventet primær avslutning: 30. apr. 2026165 deltakereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06937749

  5. Fase 2Rekrutterer

    Vosoritide in idiopathic short stature(åpner kilden i en ny fane)

    A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

    Forventet primær avslutning: juni 2026100 deltakereSponsor: BioMarin PharmaceuticalNCT06382155

  6. Fase 3Pågår, rekrutterer ikke

    SURMOUNT-ADOLESCENTS(åpner kilden i en ny fane)

    A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Primær avslutning: 2. juni 2026160 deltakereSponsor: Eli Lilly and CompanyNCT06075667

  7. Fase 3Pågår, rekrutterer ikke

    CANOPY-HCH-3(åpner kilden i en ny fane)

    Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

    Forventet primær avslutning: 1. aug. 202680 deltakereSponsor: BioMarin PharmaceuticalNCT06455059

  8. Fase 3Rekrutterer

    Mazdutide in hypertension(åpner kilden i en ny fane)

    Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

    Forventet primær avslutning: 1. aug. 2026336 deltakereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT07469800

  9. Fase 3Pågår, rekrutterer ikke

    TRANSCEND-T2D-2(åpner kilden i en ny fane)

    Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    Primær avslutning: 27. aug. 20261 250 deltakereSponsor: Eli Lilly and CompanyNCT06260722

  10. Fase 2Pågår, rekrutterer ikke

    INFLAM MOTION(åpner kilden i en ny fane)

    A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

    Primær avslutning: 31. aug. 2026129 deltakereSponsor: 4Moving BiotechNCT07225829

  11. Fase 2Pågår, rekrutterer ikke

    Mazdutide in heart failure(åpner kilden i en ny fane)

    A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

    Forventet primær avslutning: 24. sep. 2026141 deltakereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06862908

  12. Fase 2Pågår, rekrutterer ikke

    Linaclotide in colorectal neoplasia(åpner kilden i en ny fane)

    Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

    Forventet primær avslutning: 30. sep. 2026150 deltakereSponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT03796884

  13. Fase 2Rekrutterer

    OxyTUTION(åpner kilden i en ny fane)

    Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

    Forventet primær avslutning: oktober 2026112 deltakereSponsor: University Hospital, Basel, SwitzerlandNCT06036004

  14. Fase 2Rekrutterer ikke ennå

    Sublingual oxytocin for PPH(åpner kilden i en ny fane)

    Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

    Forventet primær avslutning: 30. okt. 2026330 deltakereSponsor: Insud PharmaNCT06968481

  15. Fase 3Pågår, rekrutterer ikke

    SURPASS-T1D-1(åpner kilden i en ny fane)

    A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

    Forventet primær avslutning: november 2026905 deltakereSponsor: Eli Lilly and CompanyNCT06914895

  16. Fase 3Pågår, rekrutterer ikke

    TRIUMPH-5(åpner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Forventet primær avslutning: november 2026800 deltakereSponsor: Eli Lilly and CompanyNCT06662383

  17. Fase 3Pågår, rekrutterer ikke

    OVELIA(åpner kilden i en ny fane)

    Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

    Forventet primær avslutning: 30. nov. 2026250 deltakereSponsor: Tolmar Inc.NCT04906395

  18. Fase 2Pågår, rekrutterer ikke

    LOCITT(åpner kilden i en ny fane)

    The Long COVID Treatment Trial

    Forventet primær avslutning: desember 20261 000 deltakereSponsor: Scripps Translational Science InstituteNCT07128082

  19. Fase 3Pågår, rekrutterer ikke

    GLORY-3(åpner kilden i en ny fane)

    A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

    Forventet primær avslutning: 31. des. 2026479 deltakereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06884293

  20. Fase 2Pågår, rekrutterer ikke

    FAST-Healing(åpner kilden i en ny fane)

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

    Forventet primær avslutning: februar 202796 deltakereSponsor: Hospital for Special Surgery, New YorkNCT03841058

  21. Fase 2, Fase 3Rekrutterer

    Thy-α1 for RIF(åpner kilden i en ny fane)

    Thymosin-α1 for Recurrent Implantation Failure

    Forventet primær avslutning: februar 2027136 deltakereSponsor: Fakih IVF Fertility CenterNCT07675980

  22. Fase 3Pågår, rekrutterer ikke

    Teduglutide in Chinese adults with SBS(åpner kilden i en ny fane)

    A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

    Forventet primær avslutning: 10. feb. 202713 deltakereSponsor: TakedaNCT06973304

  23. Fase 2Rekrutterer

    INHALE-1st(åpner kilden i en ny fane)

    INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

    Forventet primær avslutning: mars 2027100 deltakereSponsor: Mannkind CorporationNCT07224321

  24. Fase 3Rekrutterer

    Congenital hypothalamic obesity(åpner kilden i en ny fane)

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Forventet primær avslutning: 13. mars 202739 deltakereSponsor: Rhythm Pharmaceuticals, Inc.NCT06760546

  25. Fase 3Rekrutterer

    Liraglutide for delirium after surgery(åpner kilden i en ny fane)

    Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

    Forventet primær avslutning: 31. mars 2027260 deltakereSponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06361238

  26. Fase 3Rekrutterer

    Thymosin alpha-1 in colorectal cancer(åpner kilden i en ny fane)

    Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

    Forventet primær avslutning: 31. mars 20272 500 deltakereSponsor: Fudan UniversityNCT05086614

  27. Fase 3Rekrutterer ikke ennå

    Oral insulin ORMD-0801 in T2D(åpner kilden i en ny fane)

    A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

    Forventet primær avslutning: 25. apr. 2027300 deltakereSponsor: Oramed, Ltd.NCT06731075

  28. Fase 3Rekrutterer ikke ennå

    Abaloparatide vs teriparatide in China(åpner kilden i en ny fane)

    To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

    Forventet primær avslutning: mai 2027282 deltakereSponsor: Qilu Pharmaceutical Co., Ltd.NCT06898060

  29. Fase 3Rekrutterer

    GLORY-OSA(åpner kilden i en ny fane)

    A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

    Forventet primær avslutning: 7. mai 2027260 deltakereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06931028

  30. Fase 3Pågår, rekrutterer ikke

    RENEW 1(åpner kilden i en ny fane)

    Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

    Forventet primær avslutning: 11. mai 2027300 deltakereSponsor: Novo Nordisk A/SNCT07220642

  31. Fase 3Pågår, rekrutterer ikke

    RENEW 2(åpner kilden i en ny fane)

    Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

    Forventet primær avslutning: 12. mai 2027330 deltakereSponsor: Novo Nordisk A/SNCT07220759

  32. Fase 3Pågår, rekrutterer ikke

    ReNEW(åpner kilden i en ny fane)

    ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

    Forventet primær avslutning: august 2027313 deltakereSponsor: Stealth BioTherapeutics Inc.NCT06373731

  33. Fase 3Pågår, rekrutterer ikke

    Adjuvant leuprorelin after prostatectomy(åpner kilden i en ny fane)

    Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

    Forventet primær avslutning: september 2027700 deltakereSponsor: UNICANCERNCT01442246

  34. Fase 3Rekrutterer

    OPIC(åpner kilden i en ny fane)

    Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

    Forventet primær avslutning: september 20271 494 deltakereSponsor: University Hospital, ToursNCT04949633

  35. Fase 3Pågår, rekrutterer ikke

    TRIUMPH-7(åpner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

    Forventet primær avslutning: september 2027586 deltakereSponsor: Eli Lilly and CompanyNCT07035093

  36. Fase 3Pågår, rekrutterer ikke

    REDEFINE 3(åpner kilden i en ny fane)

    REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

    Forventet primær avslutning: 1. sep. 20277 101 deltakereSponsor: Novo Nordisk A/SNCT05669755

  37. Fase 2Rekrutterer

    TAB(åpner kilden i en ny fane)

    Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Forventet primær avslutning: 30. sep. 2027310 deltakereSponsor: T. John Winhusen, PhDNCT06651177

  38. Fase 3Pågår, rekrutterer ikke

    SURMOUNT-MMO(åpner kilden i en ny fane)

    A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

    Forventet primær avslutning: oktober 202715 374 deltakereSponsor: Eli Lilly and CompanyNCT05556512

  39. Fase 3Pågår, rekrutterer ikke

    ADOPT(åpner kilden i en ny fane)

    Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

    Forventet primær avslutning: 21. okt. 2027280 deltakereSponsor: University Medical Center GroningenNCT04302454

  40. Fase 3Rekrutterer

    GLORY-YOUNG(åpner kilden i en ny fane)

    A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

    Forventet primær avslutning: 31. okt. 2027180 deltakereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT07255209

  41. Fase 3Pågår, rekrutterer ikke

    FOCUS(åpner kilden i en ny fane)

    A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

    Forventet primær avslutning: 7. nov. 20271 500 deltakereSponsor: Novo Nordisk A/SNCT03811561

  42. Fase 2Rekrutterer ikke ennå

    ARTIST-CKD(åpner kilden i en ny fane)

    Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

    Forventet primær avslutning: 30. nov. 2027120 deltakereSponsor: University Medical Center GroningenNCT07206290

  43. Fase 3Rekrutterer

    AWARD-PEDS PLUS(åpner kilden i en ny fane)

    A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

    Forventet primær avslutning: desember 202755 deltakereSponsor: Eli Lilly and CompanyNCT06739122

  44. Fase 3Rekrutterer

    Survodutide in type 2 diabetes(åpner kilden i en ny fane)

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Forventet primær avslutning: 17. jan. 2028600 deltakereSponsor: Boehringer IngelheimNCT07754461

  45. Fase 2Rekrutterer

    TRIUMPH (tesamorelin)(åpner kilden i en ny fane)

    Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

    Forventet primær avslutning: 16. juni 2028100 deltakereSponsor: Massachusetts General HospitalNCT06554717

  46. Fase 3Rekrutterer

    AMAZE 9(åpner kilden i en ny fane)

    AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    Forventet primær avslutning: 27. juni 2028950 deltakereSponsor: Novo Nordisk A/SNCT07720271

  47. Fase 2Rekrutterer

    Vosoritide in infant hypochondroplasia(åpner kilden i en ny fane)

    A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

    Forventet primær avslutning: 30. juni 202860 deltakereSponsor: BioMarin PharmaceuticalNCT07126262

  48. Fase 3Rekrutterer

    AMAZE 3(åpner kilden i en ny fane)

    AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

    Forventet primær avslutning: 12. juli 2028300 deltakereSponsor: Novo Nordisk A/SNCT07571005

  49. Fase 3Rekrutterer ikke ennå

    SYNCHRONIZE-HERA(åpner kilden i en ny fane)

    SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

    Forventet primær avslutning: 26. juli 2028600 deltakereSponsor: Boehringer IngelheimNCT07850050

  50. Fase 3Rekrutterer

    AMBITION 7(åpner kilden i en ny fane)

    AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

    Forventet primær avslutning: 31. juli 20281 778 deltakereSponsor: Novo Nordisk A/SNCT07797335

  51. Fase 3Rekrutterer

    AMAZE 2(åpner kilden i en ny fane)

    AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Forventet primær avslutning: 7. aug. 2028630 deltakereSponsor: Novo Nordisk A/SNCT07533175

  52. Fase 3Rekrutterer

    AMAZE 5(åpner kilden i en ny fane)

    A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    Forventet primær avslutning: 14. aug. 2028400 deltakereSponsor: Novo Nordisk A/SNCT07481630

  53. Fase 2Rekrutterer

    CBCT-OT RCT(åpner kilden i en ny fane)

    Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

    Forventet primær avslutning: 30. sep. 2028240 deltakereSponsor: VA Office of Research and DevelopmentNCT06194851

  54. Fase 3Rekrutterer

    AMAZE 7(åpner kilden i en ny fane)

    A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    Forventet primær avslutning: 10. okt. 2028650 deltakereSponsor: Novo Nordisk A/SNCT07668414

  55. Fase 2, Fase 3Rekrutterer

    Pulsatile GnRH in Down syndrome(åpner kilden i en ny fane)

    GnRH Therapy on Cognition in Down Syndrome

    Forventet primær avslutning: desember 202856 deltakereSponsor: Nelly PitteloudNCT04390646

  56. Fase 3Rekrutterer ikke ennå

    AMAZE 8(åpner kilden i en ny fane)

    AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Forventet primær avslutning: 12. des. 20281 000 deltakereSponsor: Novo Nordisk A/SNCT07400107

Avsluttet eller stanset

  1. Fase 2Fullført

    Thymosin alpha-1 in lung cancer(åpner kilden i en ny fane)

    The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

    Primær avslutning: 30. juni 2026114 deltakereSponsor: Sun Yat-sen UniversityNCT06139419

  2. Fase 3Fullført

    TRIUMPH-2(åpner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

    Primær avslutning: 16. juni 20261 152 deltakereSponsor: Eli Lilly and CompanyNCT05929079

  3. Fase 3Fullført

    SYNCHRONIZE-CVOT(åpner kilden i en ny fane)

    A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

    Primær avslutning: 1. juni 20265 531 deltakereSponsor: Boehringer IngelheimNCT06077864

  4. Fase 3Fullført

    TRIUMPH-3(åpner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

    Primær avslutning: 16. apr. 20261 946 deltakereSponsor: Eli Lilly and CompanyNCT05882045

  5. Fase 2Fullført

    COPE+OT(åpner kilden i en ny fane)

    Oxytocin to Enhance Integrated Treatment for AUD and PTSD

    Primær avslutning: 13. apr. 2026175 deltakereSponsor: Medical University of South CarolinaNCT04523922

  6. Fase 3Fullført

    TRIUMPH-1(åpner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

    Primær avslutning: 6. apr. 20262 335 deltakereSponsor: Eli Lilly and CompanyNCT05929066

  7. Fase 2Fullført

    Mazdutide in alcohol use disorder(åpner kilden i en ny fane)

    A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

    Primær avslutning: 19. mars 2026308 deltakereSponsor: Eli Lilly and CompanyNCT06817356

  8. Fase 3Fullført

    TRANSCEND-T2D-1(åpner kilden i en ny fane)

    Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

    Primær avslutning: 22. jan. 2026537 deltakereSponsor: Eli Lilly and CompanyNCT06354660

  9. Fase 3Fullført

    TOGETHER-PsO(åpner kilden i en ny fane)

    Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

    Primær avslutning: 8. jan. 2026281 deltakereSponsor: Eli Lilly and CompanyNCT06588283

  10. Fase 3Fullført

    EMANATE(åpner kilden i en ny fane)

    EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

    Primær avslutning: 22. des. 2025296 deltakereSponsor: Rhythm Pharmaceuticals, Inc.NCT05093634

  11. Fase 3Fullført

    SYNCHRONIZE-2(åpner kilden i en ny fane)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

    Primær avslutning: 12. des. 2025755 deltakereSponsor: Boehringer IngelheimNCT06066528

  12. Fase 3Fullført

    CagriSema vs tirzepatide in obesity(åpner kilden i en ny fane)

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    Primær avslutning: 8. des. 2025809 deltakereSponsor: Novo Nordisk A/SNCT06131437

  13. Fase 3Fullført

    Leuprolide mesylate in early puberty(åpner kilden i en ny fane)

    Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

    Primær avslutning: 7. des. 202594 deltakereSponsor: Foresee Pharmaceuticals Co., Ltd.NCT05493709

  14. Fase 3Fullført

    SYNCHRONIZE-1(åpner kilden i en ny fane)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

    Primær avslutning: 2. des. 2025726 deltakereSponsor: Boehringer IngelheimNCT06066515

  15. Fase 3Fullført

    REIMAGINE 2(åpner kilden i en ny fane)

    A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Primær avslutning: 19. nov. 20252 734 deltakereSponsor: Novo Nordisk A/SNCT06065540

  16. Fase 3Fullført

    TRIUMPH-4(åpner kilden i en ny fane)

    A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

    Primær avslutning: 14. nov. 2025445 deltakereSponsor: Eli Lilly and CompanyNCT05931367

  17. Fase 2Fullført

    Exenatide for smoking cessation(åpner kilden i en ny fane)

    Exenatide for Smoking Cessation and Prevention of Weight Gain

    Primær avslutning: 7. nov. 2025140 deltakereSponsor: The University of Texas Health Science Center, HoustonNCT05610800

  18. Fase 3Fullført

    SYNCHRONIZE-MASLD(åpner kilden i en ny fane)

    A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

    Primær avslutning: 9. okt. 2025218 deltakereSponsor: Boehringer IngelheimNCT06309992

  19. Fase 2Fullført

    Amycretin in type 2 diabetes(åpner kilden i en ny fane)

    A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

    Primær avslutning: 1. okt. 2025448 deltakereSponsor: Novo Nordisk A/SNCT06542874

  20. Fase 3Fullført

    DREAMS-3(åpner kilden i en ny fane)

    A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

    Primær avslutning: 17. sep. 2025349 deltakereSponsor: Innovent Biologics (Suzhou) Co. Ltd.NCT06184568

  21. Fase 3Fullført

    EVOKE(åpner kilden i en ny fane)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

    Primær avslutning: 16. sep. 20251 840 deltakereSponsor: Novo Nordisk A/SNCT04777396

  22. Fase 3Fullført

    EVOKE Plus(åpner kilden i en ny fane)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

    Primær avslutning: 15. sep. 20251 840 deltakereSponsor: Novo Nordisk A/SNCT04777409

  23. Fase 3FullførtResultater publisert

    Linaclotide in constipation, ages 2 to 5(åpner kilden i en ny fane)

    A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

    Primær avslutning: 2. sep. 2025123 deltakereSponsor: AbbVieNCT05652205

  24. Fase 2Fullført

    SEMALCO(åpner kilden i en ny fane)

    Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

    Primær avslutning: 31. juli 2025108 deltakereSponsor: Psychiatric Centre RigshospitaletNCT05895643